Plasmodium falciparum merozoite surface protein 3 (MSP3) (MSP3)

Plasmodium falciparum merozoite surface protein 3 (MSP3) is a 48-kDa secreted protein located on the surface of the merozoite stage of the malaria parasite (UniProt: P13828). It is characterized by a series of heptad repeats and a C-terminal leucine zipper motif, which are involved in the attachment of merozoites to human erythrocytes (PubMed: 11520451). MSP3 is a primary target for vaccine development because it is relatively conserved across different parasite strains and is a target of naturally acquired protective immunity in humans (PubMed: 25637591). The therapeutic mechanism involves the induction of specific IgG1 and IgG3 antibodies that do not necessarily block invasion directly but instead mediate Antibody-Dependent Cellular Inhibition (ADCI). In this process, antibodies coat the merozoite and interact with Fc-gamma receptors on monocytes, triggering the release of soluble factors that inhibit the growth of intra-erythrocytic parasites (PubMed: 21844301). Clinical vaccine candidates such as the Long Synthetic Peptide (MSP3-LSP) and the GMZ2 fusion protein (a combination of MSP3 and GLURP) have been developed to elicit these protective immune responses and reduce parasite burden in endemic populations (PubMed: 25637591). These interventions aim to provide long-lasting immunity against the asexual blood stage of P. falciparum, which is responsible for the clinical symptoms of malaria.

Other names

MSP-3Merozoite surface protein 3PfMSP3Secreted polymorphic antigen associated with the leucine zipperSPALTE

Induction of specific IgG1 and IgG3 antibodies that mediate Antibody-Dependent Cellular Inhibition (ADCI), where monocytes are triggered to release parasite-inhibitory factors upon binding to antibody-coated merozoites (PubMed: 21844301).